Two Sigma Advisers LP raised its stake in Encompass Health Co. (NYSE:EHC - Free Report) by 136.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 63,800 shares of the company's stock after acquiring an additional 36,800 shares during the period. Two Sigma Advisers LP owned approximately 0.06% of Encompass Health worth $5,892,000 as of its most recent SEC filing.
A number of other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in shares of Encompass Health by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 10,404,081 shares of the company's stock worth $960,817,000 after acquiring an additional 138,196 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Encompass Health by 3.3% during the fourth quarter. Invesco Ltd. now owns 5,536,251 shares of the company's stock valued at $511,273,000 after purchasing an additional 176,135 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in shares of Encompass Health by 6.0% during the fourth quarter. Alliancebernstein L.P. now owns 2,076,869 shares of the company's stock valued at $191,799,000 after purchasing an additional 117,617 shares in the last quarter. FMR LLC lifted its holdings in shares of Encompass Health by 0.8% during the fourth quarter. FMR LLC now owns 1,973,846 shares of the company's stock valued at $182,285,000 after purchasing an additional 15,831 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Encompass Health by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 1,679,774 shares of the company's stock valued at $155,176,000 after purchasing an additional 6,164 shares in the last quarter. 97.25% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of research analysts have recently issued reports on EHC shares. William Blair reaffirmed an "outperform" rating on shares of Encompass Health in a report on Friday, February 7th. KeyCorp upped their price target on Encompass Health from $122.00 to $135.00 and gave the company an "overweight" rating in a report on Tuesday. UBS Group upped their price target on Encompass Health from $117.00 to $130.00 and gave the company a "buy" rating in a report on Monday, April 28th. Wall Street Zen raised Encompass Health from a "buy" rating to a "strong-buy" rating in a report on Saturday, May 24th. Finally, Royal Bank of Canada increased their target price on Encompass Health from $110.00 to $125.00 and gave the company an "outperform" rating in a report on Monday, April 28th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $122.71.
Get Our Latest Stock Report on EHC
Insider Buying and Selling
In other Encompass Health news, CEO Mark J. Tarr sold 118,384 shares of the firm's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $121.53, for a total transaction of $14,387,207.52. Following the completion of the transaction, the chief executive officer now owns 527,070 shares in the company, valued at $64,054,817.10. This trade represents a 18.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Elissa Joy Charbonneau sold 4,279 shares of the firm's stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $116.61, for a total value of $498,974.19. Following the completion of the sale, the insider now directly owns 11,958 shares of the company's stock, valued at $1,394,422.38. The trade was a 26.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 132,663 shares of company stock worth $16,034,082. 2.00% of the stock is owned by corporate insiders.
Encompass Health Stock Performance
Shares of NYSE EHC traded up $1.06 during trading on Friday, hitting $121.07. The company had a trading volume of 106,540 shares, compared to its average volume of 781,476. The stock has a 50 day simple moving average of $109.52 and a 200 day simple moving average of $101.88. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.04 and a current ratio of 1.05. Encompass Health Co. has a 12 month low of $82.74 and a 12 month high of $121.96. The firm has a market capitalization of $12.20 billion, a P/E ratio of 27.14, a price-to-earnings-growth ratio of 2.31 and a beta of 0.91.
Encompass Health (NYSE:EHC - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The company reported $1.37 EPS for the quarter, topping the consensus estimate of $1.19 by $0.18. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. The firm had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.43 billion. During the same quarter last year, the company earned $1.12 earnings per share. The business's revenue for the quarter was up 10.6% compared to the same quarter last year. As a group, analysts anticipate that Encompass Health Co. will post 4.8 earnings per share for the current year.
Encompass Health Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Tuesday, July 1st will be given a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a dividend yield of 0.56%. The ex-dividend date is Tuesday, July 1st. Encompass Health's dividend payout ratio is currently 14.05%.
About Encompass Health
(
Free Report)
Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.
Featured Articles
Before you consider Encompass Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Encompass Health wasn't on the list.
While Encompass Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
